Shawview Consulting has strategic partnerships with several individuals and organisations who are available to work on projects with Shawview. Current partners with Shawview include those listed here.
Policy, legal and strategy consultant
Andrew Jenner is Executive Director of Jenner Strategic Consulting offering offers experienced public affairs and business consultancy services. Before forming Jenner Strategic Consulting in 2014 based in the UK, Andrew was Executive Director of Corporate Strategy & Legal Affairs at the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) in Geneva. Prior to this Andrew was Head of Trade and Development for the UK Government’s Intellectual Property Office (IPO), where he led the UK Government delegation to the World Trade Organization and the World Intellectual Property Organization, as well as being the principal EU negotiator on the World Health Organization’s negotiations on Public Health, Innovation and IP. Andrew holds a Bachelor of Engineering degree with honours, a Diploma in Law and Intellectual Property and Master of Laws from the University of Wales.
Global health consultant
Evan Lee is a Geneva-based consultant and an expert in global health policy. He has previously worked for pharmaceutical company Eli Lilly as Vice President Global Health and Programs, the Senior Adviser to Foundation for Innovative New Diagnostics (FIND), a consultant with Management Sciences for Health and Medical Coordinator with Medicines Sans Frontieres. He has worked on many global health and access to medicines issues including diabetes, cardiovascular disease in low- and middle-income countries, public affairs and business strategy. A medically qualified doctor by training, he has a BA in chemistry and physics from Harvard University, a medical degree from New York University School of Medicine and an MBA from Massachusetts Institute of Technology.
Jorge Mestre-Ferrandiz is an independent economics consultant, based in Madrid, Spain, having spent 15 years at The Office of Health Economics with various positions including as an Industrial Economist and as Director of Consulting. Jorge has over 15 years’ experience consulting to the pharmaceutical industry and related non-profit organisations and his clients have included a number of global top 30 pharmaceutical companies and a range of NGOs. He specialises in the economics of the industry, the pricing and reimbursement of medicines, the impact of public policy on innovation, market access, the economics of antimicrobial resistance (AMR), and pharmaceutical product portfolios. Jorge has a PhD in Economic Analysis from the University Autonoma of Barcelona, has published over 50 papers on health economics and is regularly invited to speak on related topics at academic and commercial international conferences. He is a Visiting Fellow at OHE, Director, Oxford Martin Programme on Affordable Medicines, Oxford Martin School, University of Oxford, an Honorary Visiting Lecturer at the Department of Economics, City University London, and Health Economics Professor at Instituto de Empresa (IE) Business School, Madrid.
Siddhartha has extensive experience in health systems, pharmaceutical policy, intellectual property, pricing, reimbursement, innovative business models and access to medicines. Siddhartha has worked with international organisations such as the World Trade Organization, World Health Organization and the World Bank as well as several international pharmaceutical companies, device companies and consulting firms. Siddhartha has over 20 years of experience working in emerging markets in Asia and Africa on public private partnerships and facilitating cross-sectoral dialogue on policy options and access strategies. He holds a degree in geography from University College London and a masters in the economic history of developing countries from the London School of Economics.
Rob has over 20 years’ experience advising health and medical technology companies on market entry, M&A, business planning, investment and venture capital raising in the Chinese health market. He has previously worked in related senior roles for EY, Austrade and the Queensland state government. For the last 10 years, Rob has run an advisory business based in Shanghai for life sciences and medical technology companies seeking to enter China and Chinese investment funds. Rob has worked with clients to navigate the complex and evolving Chinese life sciences market and regulatory landscape. He advises in market entry; due diligence; partner development; distribution, contract and licence negotiation; commercialisation; clinical trial and regulatory support. Rob is a member of the Australian Institute of Company Directors and formerly Executive Director of the Australia-China Business Council. He holds an MBA from Griffith University and a Master of Public Health from the Queensland University of Technology.
Health Economics and Policy Consultant
Ambrish is an experienced expert in health economics and policy and supports Shawview Consulting's Australian and Asia-Pacific practice. Based in Hobart, Australia, Ambrish has substantial experience in health economics, health technology assessment, outcomes research, real-world evidence, and reimbursement policy. He is a regular academic author with an extensive publication list in health economics, outcomes research, and real-world evidence. He has previously worked in the public, private, and higher education sectors as a university researcher, independent consultant, pharmacovigilance scientist, and communications manager. He has also held health economist and market access roles with several consulting, pharmaceutical, and medical device companies in India. Ambrish holds a Diploma in Pharmacy from Delhi University, a Bachelor of Pharmacy from Dr. A.P.J. Abdul Kalam Technical University, and a Master of Technology in Biotechnology from Anna University. Ambrish is currently studying for a PhD in Medical Studies at the Menzies Institute for Medical Research at the University of Tasmania.
Regulatory, Medical and Pharmacovigilance Global Policy Consultant
Sunayana Shah is an expert in regulatory, scientific, medical, pharmacovigilance policy and issues at national and international level. Based in London, she has extensive experience in complex stakeholder management, policy analysis and communication, particularly in complex technical scientific areas. Sunayana previously was Head of Regulatory and Safety Policy at the Association of the British Pharmaceutical Industry (ABPI) where she advised the pharmaceutical industry and worked with UK, European and international agencies on international regulatory policy issues, including Brexit. Previously, she led scientific and medical affairs at the Proprietary Association of Great Britain (PAGB) leading on national and international OTC policy, regulatory issues and professional programs. She has also been Senior Staff editor of the British National Formulary, Royal Pharmaceutical Society and has extensive community pharmacy experience. Sunayana holds an honours degree from the School of Pharmacy, University of London, and Post Graduate Diplomas in Evidence based Pharmacotherapy (Aston University) and Community Pharmacy (University of Keele). She is a GPhC registered pharmacist and a Fellow and Ambassador of the Royal Pharmaceutical Society.
Government affairs and public policy consultant
Chris Strutt has over 30 years’ experience as an adviser and strategist in government affairs and public policy. Now a consultant, Chris was most recently Senior Vice-President (SVP) and Special Adviser to the CEO and Corporate Executive Team at global pharmaceutical company GSK. He previously held various senior government affairs and public policy positions at GSK, and prior to this worked in consultancy and in senior policy positions in the UK Government. Chris’ substantial experience ranges across a wide range of issues, stakeholders and geographies, and his expertise includes political strategy, risk assessment, policy analysis, and reputation and crisis management. Chris has an honours degree in History from Cambridge University.
Rebecca has over 20 years of experience in the field of health technology assessment (HTA). Now based in Australia, she has previously worked as an adviser and consultant for the National Institute for Health and Clinical Excellence (NICE) in the UK where she conducted and supervised the production of HTAs, contributed to the development of the NICE Methods Guide, provided scientific advice to pharmaceutical companies and provided training and policy advice to governments around the world. She has also been a senior officer within the Western Australian Department of Health conducting state-based HTA for medical devices, initiation of a disinvestment program and workforce and service planning. She has also held roles as the Director of Scientific Initiatives at Health Technology Assessment international (HTAi), working on policy matters with senior users and producers of HTA (including industry, HTA agencies and policy makers and payers) around the globe and also established the Australian Clinical Trials: Impact & Quality (CT:IQ) initiative. Rebecca holds an MSc in Health Services Research and a BSc in mathematics and statistics, and has formal training in systematic reviewing and health economics.
Our Corporate Partners
PharmaSymbiosis is a specialist African consulting and services company providing a variety of services to the health and pharmaceutical sector. The firm helps clients address health care challenges, access opportunities, and to compete more effectively in African markets through the services including market research, consulting, product life cycle management, marketing, regulatory, health policy support, pharmacovigilance and public health initiative support. PharmaSymbiosis operates in Ghana, Ivory Coast, Kenya, Nigeria and Sierra Leone.